933 / 1983
NCT01603420
Proton Collaborative Group
Primary endpoint: 5-year Freedom From Failure (FFF) Rates
Random
RT 79.2 Gy(RBE)+ ADT 24 m.
RT 79.2 Gy(RBE) + ADT 6 m.
+
Weekly Docetaxel (20mg/m2 IV)
Trial is completed. Results are pending